Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Recipient : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Everest Medicines Announces Regulatory Update and Strategic Partnership for Xerava in Taiwan
Details : Xerava™ (eravacycline) is a novel, fully synthetic, broad-spectrum, fluorocycline, parenteral antibiotic of the tetracycline class that has shown broad in vitro activity against Gram-negative and Gram-positive pathogens that have acquired multidrug res...
Product Name : Xerava
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 08, 2022
Lead Product(s) : Eravacycline
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Recipient : Everest Medicines
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Polymyxin B Sulfate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 04, 2022
Lead Product(s) : Polymyxin B Sulfate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study of S-1 Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer in Taiwan
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2019
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Study Phase : Undisclosed
Recipient : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 13, 2018
Lead Product(s) : Fentanyl
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Recipient : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 07, 2018
S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2017
Lead Product(s) : Megestrol Acetate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 02, 2016
Lead Product(s) : Megestrol Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 04, 2016
Lead Product(s) : Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 23, 2015
Lead Product(s) : Sodium Alginate
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Recipient : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 29, 2014
Lead Product(s) : Sodium Alginate
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Recipient : Chang Gung Memorial Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
